Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

NCT04163900 is registered in ClinicalTrials.gov with NuCana plc as lead sponsor.

NCT NCT04163900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04163900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
Lead sponsor
NuCana plc
Phase
Phase 3
Overall status
Terminated
Start date
December 24, 2019
Completion date
April 5, 2022
Enrollment
773 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer